|
|
||||||||
-cardiac myosin in the laser trap assay1Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, Vermont; 2Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany; 3Department of Physiology and Biophysics, Boston University School of Medicine, Boston; 4Department of Genetics and Howard Hughes Medical Institute, Harvard Medical School, Boston; and 5Cardiovascular Division and 6Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, Massachusetts
Submitted 31 January 2007 ; accepted in final form 3 March 2007
Point mutations in cardiac myosin, the heart's molecular motor, produce distinct clinical phenotypes: hypertrophic (HCM) and dilated (DCM) cardiomyopathy. Do mutations alter myosin's molecular mechanics in a manner that is predictive of the clinical outcome? We have directly characterized the maximal force-generating capacity (Fmax) of two HCM (R403Q, R453C) and two DCM (S532P, F764L) mutant myosins isolated from homozygous mouse models using a novel load-clamped laser trap assay. Fmax was 50% (R403Q) and 80% (R453C) greater for the HCM mutants compared with the wild type, whereas Fmax was severely depressed for one of the DCM mutants (65% S532P). Although Fmax was normal for the F764L DCM mutant, its actin-activated ATPase activity and actin filament velocity (Vactin) in a motility assay were significantly reduced (Schmitt JP, Debold EP, Ahmad F, Armstrong A, Frederico A, Conner DA, Mende U, Lohse MJ, Warshaw D, Seidman CE, Seidman JG. Proc Natl Acad Sci USA 103: 1452514530, 2006.). These Fmax data combined with previous Vactin measurements suggest that HCM and DCM result from alterations to one or more of myosin's fundamental mechanical properties, with HCM-causing mutations leading to enhanced but DCM-causing mutations leading to depressed function. These mutation-specific changes in mechanical properties must initiate distinct signaling cascades that ultimately lead to the disparate phenotypic responses observed in HCM and DCM.
familial hypertrophic cardiomyopathy; in vitro motility; force-velocity relationship; heart failure
This article has been cited by other articles:
![]() |
C. Y. Ho, C. Carlsen, J. J. Thune, O. Havndrup, H. Bundgaard, F. Farrohi, J. Rivero, A. L. Cirino, P. S. Andersen, M. Christiansen, et al. Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic Cardiomyopathy Circ Cardiovasc Genet, August 1, 2009; 2(4): 314 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mestroni Phenotypic heterogeneity of sarcomeric gene mutations: a matter of gain and loss? J. Am. Coll. Cardiol., July 21, 2009; 54(4): 343 - 345. [Full Text] [PDF] |
||||
![]() |
B. M. Palmer, Y. Wang, P. Teekakirikul, J. T. Hinson, D. Fatkin, S. Strouse, P. VanBuren, C. E. Seidman, J. G. Seidman, and D. W. Maughan Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1939 - H1947. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Morimoto Sarcomeric proteins and inherited cardiomyopathies Cardiovasc Res, March 1, 2008; 77(4): 659 - 666. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |